Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

A Phase II, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects With Congestive Heart Failure

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00259038

Enrollment

162

Registered

2005-11-29

Start date

2004-01-31

Completion date

2006-02-28

Last updated

2016-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Decompensation, Heart Failure, Congestive, Left Ventricular Failure, Myocardiopathies, Systolic or Diastolic Left Ventricular Dysfunction

Keywords

Carperitide, Atrial Natriuretic Peptide, Treatment efficacy, Safety, Heart failure, Congestive, Pulmonary Artery Catheterization

Brief summary

The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.

Interventions

DRUGCarperitide

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Is hospitalized with congestive heart failure (CHF) * Has a Swan-Ganz catheter inserted for CHF management and has pulmonary capillary wedge pressure 18 mmHg or higher

Exclusion criteria

* Has had a heart transplant * Requires mechanical ventilation or mechanical circulatory support

Design outcomes

Primary

Measure	Time frame
Change from baseline in pulmonary capillary wedge pressure (PCWP)	at 3 hours following initiation of study drug infusion

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026